Gemcitabine Combined with the mTOR Inhibitor Temsirolimus in Patients with Locally Advanced or Metastatic Pancreatic Cancer. A Hellenic Cooperative Oncology Group Phase I/II Study-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Gemcitabine Combined with the mTOR Inhibitor Temsirolimus in Patients with Locally Advanced or Metastatic Pancreatic Cancer. A Hellenic Cooperative Oncology Group Phase I/II Study

Published:2018-11-28 Issue:6 Volume:13 Page:715-724
ISSN:1776-2596
Container-title:Targeted Oncology
language:en
Short-container-title:Targ Oncol

Author:

Karavasilis Vasilios,Samantas Epaminontas,Koliou Georgia-Angeliki,Kalogera-Fountzila Anna,Pentheroudakis George,Varthalitis Ioannis,Linardou Helena,Rallis Grigorios,Skondra Maria,Papadopoulos Georgios,Papatsibas George,Sgouros Joseph,Goudopoulou Athina,Kalogeras Konstantine T.,Dervenis Christos,Pectasides Dimitrios,Fountzilas George

Funder

Pfizer Inc

Hellenic Cooperative Oncology Group

Hellenic Study Group for Metastatic Liver Disease

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Cancer Research,Oncology

Link

http://link.springer.com/article/10.1007/s11523-018-0605-y/fulltext.html

Reference30 articles.

1. Bekaii-Saab T, Goldberg R. Therapeutic advances in pancreatic cancer: miles to go before we sleep. J Natl Cancer Inst. 2015;107(2). https://doi.org/10.1093/jnci/dju439 .

2. Enewold L, Harlan LC, Tucker T, McKenzie S. Pancreatic Cancer in the USA: persistence of Undertreatment and poor outcome. J Gastrointest Cancer. 2015;46(1):9–20. https://doi.org/10.1007/s12029-014-9668-x .

3. Walker EJ, Ko AH. Beyond first-line chemotherapy for advanced pancreatic cancer: an expanding array of therapeutic options? World J Gastroenterol. 2014;20(9):2224–36. https://doi.org/10.3748/wjg.v20.i9.2224.

4. Hidalgo M. New insights into pancreatic cancer biology. Ann Oncol. 2012;23(Suppl 10):x135–8. https://doi.org/10.1093/annonc/mds313.

5. Mohammed S, Van Buren G 2nd, Fisher WE. Pancreatic cancer: advances in treatment. World J Gastroenterol. 2014;20(28):9354–60. https://doi.org/10.3748/wjg.v20.i28.9354.

Cited by 19 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Molecular Classification and Pathogenesis of Pancreatic Adenocarcinoma and Targeted Therapies: A Review;Frontiers in Bioscience-Landmark;2024-03-13

2. Clinical and Preclinical Targeting of Oncogenic Pathways in PDAC: Targeted Therapeutic Approaches for the Deadliest Cancer;International Journal of Molecular Sciences;2024-03-01

3. Targeting KRAS for the potential treatment of pancreatic ductal adenocarcinoma: Recent advancements provide hope (Review);Oncology Reports;2023-10-04

4. Combination effects of amino acid transporter LAT1 inhibitor nanvuranlat and cytotoxic anticancer drug gemcitabine on pancreatic and biliary tract cancer cells;Cancer Cell International;2023-06-15

5. Targeted therapy and drug resistance in gastric and pancreatic cancer;Treatment Landscape of Targeted Therapies in Oncology;2023

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3